Logo

Gain Therapeutics, Inc.

GANX

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore prot… read more

Healthcare

Biotechnology

2 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.78

Price

+0.57%

$0.01

Market Cap

$63.989m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$82.240k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$18.593m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.66

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$3.696m

$9.834m

Assets

$6.138m

Liabilities

$229.170k

Debt
Debt to Assets

2.3%

-

Debt to EBITDA
Free Cash Flow

-$9.532m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases